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INTRODUCTION
Irinotecan is a cytotoxic agent with a low toxicity profile
and proven activity against a number of solid tumors
[1-3]. As shown in a pharmacokinetic study, nearly 80% of
the overall clearance of irinotecan can be attributed to
nonrenal processes, including the metabolic degradation
of irinotecan [4]. However, it remains unknown whether
irinotecan is safe for administration in patients with renal
failure and whether dose adjustment is required. We
administered a standard dose of irinotecan to a hemo-
dialysis patient with limited disease small-cell lung cancer
and end-stage renal disease. The treatment with
irinotecan was safe and well tolerated. This is the first
study to report the successful treatment of a small-cell
lung cancer patient on hemodialysis with irinotecan.
CASE REPORT
A 49-yr-old man was referred to our hospital because of
chronic cough and chest pain. A computed tomography
(CT) scan revealed a right hilar lung mass without distant
metastases. Percutaneous needle lung biopsy was per-
formed, and histopathologic analysis revealed small-cell
lung cancer. Thus, the patient was diagnosed to have
limited disease small-cell lung cancer. The patient also
suffered from chronic renal failure with end-stage renal
disease most probably due to glomerulonephritis, which
was being treated with hemodialysis on a 3 times weekly
schedule for 5 years. The patient was treated with 6
courses of intravenous irinotecan for 90 min on days 1, 8,
and 15 of a 28-day cycle. Hemodialysis was performed 24
h after the administration of irinotecan. The patient was
dialyzed for 4 h through an arteriovenous shunt in his left
forearm. During the first cycle, he received a 100 mg/m
2
dose of irinotecan, and the treatment was well tolerated.
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CASE REPORT
The prognosis of patients with end-stage renal disease has improved with advances in hemodialysis
techniques. However, many patients who undergo hemodialysis suffer from various types of cancer. Limited data
is available to guide clinical management of these patients who may have impaired renal function. Here, we
report our experience with the use of irinotecan for the treatment of a hemodialysis patient with small-cell lung
cancer and end-stage renal disease. (Korean J Intern Med 2009;24:73-75)
Keywords: Small-cell lung cancer; Hemodialysis; Irinotecan
Received: January 3, 2007
Accepted: May 22, 2007
Correspondence to Chi Young Park, MD
Department of Internal Medicine, College of Medicine, Chosun University, 588 Susuk-dong, Dong-gu, Gwangju 501-717, Korea  
Tel: 82-62-220-3279, Fax: 82-62-234-9653, E-mail: pcy@chosun.ac.kr
*This study was supported by research fund from Chosun University, 2007.Hence, a dose of 100 mg/m
2 was used subsequently.
Pretreatment and nadir blood cell counts are shown in
Figure 1. Grade 2 anorexia and fatigue were observed as
non-hematological adverse effects. After the completion of
chemotherapy, the tumors showed a complete response as
assessed by CT scan (Fig. 2); the patient was then treated
with thoracic irradiation. The patient has been free of
disease for 12 months.
DISCUSSION
Clinical trials include only selected patients with a good
performance status as well as those with normal organ
functions. However, patients in practical settings some-
times have comorbidities such as chronic pulmonary
diseases, cardiovascular diseases, hepatic dysfunctions,
and renal failure. In cancer patients, renal failure is
common and is often caused by previous cytotoxic
treatment, coexisting diseases (e.g., hypertension,
diabetes) or by the tumor itself. The relatively low number
of patients with renal failure makes it difficult to conduct
pharmacokinetic studies of cytotoxic drugs in these
patients. Consequently, for many chemotherapeutic
agents, limited information is available regarding the
optimal dosing and appropriate treatment schedules for
patients suffering from varying degrees of renal failure [5-
10]. Most previous studies on chemotherapy of such
patients have reported the feasibility of administration at
lower doses rather than standard doses in a limited
number of patients [8]. Chemotherapy involving such low
doses of drug, however, has never been shown to be
sufficiently effective for the treatment of solid tumors.
Irinotecan is very effective for various forms of malignant
tumors, including small-cell lung cancer and colorectal
cancer [1-3]. Diarrhea and neutropenia are the most
common side effects of irinotecan treatment [11]. Small-
cell lung cancer is a highly chemosensitive cancer; hence,
chemotherapy has been established as the primary mode
of treatment for this cancer. Stemmler et al. [12] per-
formed chemotherapy with irinotecan for hemodialysis
patients with metastatic colorectal cancer; a gradual dose
escalation of irinotecan showed that a weekly schedule at a
dose of 80 mg/m
2 was feasible. A dose escalation to 100
mg/m
2 resulted in severe diarrhea; therefore, treatment
was continued with a weekly dose of 80 mg/m
2. However,
in the present case, we administered a dose of 100 mg/m
2
irinotecan because diarrhea is an uncommon side effect in
Korea [13]. During the treatment, the patient showed no
significant adverse effects, including diarrhea.
We conclude that the standard dose of irinotecan can be
used safely and successfully for the treatment of
hemodialysis patients with small-cell lung cancer and
end-stage renal disease, with a close follow-up of potential
adverse effects.
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Figure 1. Absolute neutrophil count (ANC) and platelet count during
chemotherapy.
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Figure 2. Thorax CT before the first cycle of irinotecan (A) and after 6 cycles (B).
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